A Year of Possible Regulatory Upheaval and Paralysis: This coming year could see a combination of regulatory uncertainty and inactivity for the pharma industry, mainly as a result of Brexit.

The article discusses the possible introduction of emergency regulations to ensure continued access of medicines after the British withdrawal from the European Union (EU) in March 2019. Topics include the regulatory uncertainty and inactivity of the pharmaceutical industry due to Brexit, the suspension or reduction of operations of the European Medicines Agency as it moves to the Netherlands and the possible disruption in the movement of medicines and clinical trials in Great Britain and EU.